- NCIt
- C3708
Loading cancer entity…
Loading cancer entity…
Clinical trials
349 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07121322 | Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.(DACT-GCT) | recruiting | Phase 2 | 33 | National Cancer Institute, SlovakiaOTHER_GOV | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04684368 | A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | recruiting | Phase 2 | 160 | Children's Oncology GroupNETWORK | 4 | Sep 23, 2026 | clinicaltrials |
| NCT05529251 | De-escalation Study for Stage IIa/IIb < 3 cm Seminoma(EDEN) | recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06368817 | A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | recruiting | Phase 2 | 240 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT06041503 | Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) | recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06866964 | A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy(ASPIRE) | recruiting | Phase 2 | 35 | Wake Forest University Health SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT04804007 | Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT | recruiting | Phase 2 | 64 | Nabil AdraOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06937866 | Maintenance Zanzalintinib With Etoposide After HDCT in GCT | recruiting | Phase 1 / Phase 2 | 38 | Indiana UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07188441 | Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin. | recruiting | Phase 2 | 40 | Chengcheng GuoOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06144736 | PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND | recruiting | Phase 2 | 60 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06418789 | High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors(GERMAN) | recruiting | Phase 2 | 25 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05455918 | Paclitaxel/Ifosfamide/Cisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor | recruiting | Phase 2 | 42 | Yonsei UniversityOTHER | 1 | Jul 13, 2022 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials